BioMarin at Morgan Stanley conference: growth, deals and pipeline bets

BioMarin said VOXZOGO is on track for approximately $1 billion in 2024 revenue after 20% Q2 patient growth, while PALYNZIQ rose 27% to $135 million in quarterly sales. The Amicus acquisition is expected to generate $200 million in annual non-GAAP expense synergies, be accretive in its first year, and support combined GALAFOLD and POMBILITI peak sales of $2.6 billion by the mid-2030s. Management pulled forward its sub-2.5x leverage target to mid-2027 and expects $4 billion-$5 billion of acquisition capacity by then, although integration of regulated systems will continue through 2025 and full synergies are not expected until 2028.

Analysis

The key valuation debate is not near-term product growth but whether BMRN can convert an acquired commercial base into structurally higher margins without impairing patient-support execution. The announced cost program is heavily back-office weighted, which lowers commercial-disruption risk, but regulated-system migration creates a long runway during which one-time costs and duplicate infrastructure can obscure reported margin expansion. The market should begin to capitalize the synergy run-rate 1-3 quarters before full realization; a clean 2027 operating-margin bridge is therefore the most important rerating catalyst.

BMRN's growth-disease franchise has an unusual hedge against ASND: royalty economics partially monetize competitor patient additions in designated markets. That makes the competitive risk more about net price, persistence, and international access than simply share loss. ASND remains the cleaner beneficiary if long-acting convenience drives switching, while BMRN has superior downside protection from its infant-positioning, broader international reimbursement infrastructure, and royalty stream. Watch ASND prescription growth and BMRN net-sales growth together: strong ASND starts without a corresponding BMRN deceleration would validate a larger category rather than a zero-sum market.

The contrarian issue is that management's long-dated peak-sales targets rely substantially on diagnosis expansion, not merely geographic rollout. Patient-finding initiatives can produce attractive returns but are difficult to forecast and vulnerable to payer friction; the acquired assets should be valued initially on current treated populations and demonstrable switching, not peak assumptions. BMN 333 is a mid-2025 binary catalyst: superior efficacy would defend franchise durability but also raises internal cannibalization risk if it requires price concessions or costly conversion of an established patient base.

Over 6-18 months, deleveraging creates strategic optionality but also revives serial-acquirer risk. BMRN deserves a higher multiple only if it demonstrates that acquisitions are funded by organic cash generation and purchased at lower risk-adjusted multiples than internally developed programs. A larger deal before integration milestones are met would likely compress the multiple, even if nominally accretive.

Key Decisions for Investors

• Initiate a 6-12 month long BMRN / short ASND pair at equal dollar exposure: BMRN offers synergy and diversification optionality, while ASND is more exposed to a single competitive-launch and reimbursement trajectory. Target 15-20% relative upside; cut if BMRN reports two consecutive quarters of material growth deceleration in its growth-disorder franchise or reduces the integration-savings outlook.
• Add BMRN on post-earnings weakness only if management reaffirms the deleveraging timeline and provides a quantified integration-cost/synergy bridge. The missing diligence item is pro forma net leverage and cash interest sensitivity; absent that disclosure, avoid treating acquisition capacity as near-term equity value.
• Use mid-2025 BMN 333 data as an event-risk hedge rather than a reason to chase BMRN beforehand: maintain limited position sizing into data, or buy defined-risk BMRN call spreads if implied volatility is below the expected clinical-event move. A failure to show clinically meaningful efficacy beyond current standard would weaken long-term franchise-duration assumptions.
• Monitor AZN as the indirect HPP read-through: successful oral HPP development could pressure the durability of its enzyme-replacement franchise over several years, but the program is too early for a standalone short. Escalate only after clinical data establish systemic benefit and tolerability, not on management market-size claims.